Location · Cullman, AL
Clinical trials in Cullman, AL
11 recruiting studies have a site in Cullman, and 0 of them accept healthy volunteers.
11 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
TG Therapeutics, Inc.
- Location
- Cullman, AL + 35 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Location
- Cullman, AL + 51 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
Sanofi
- Location
- Cullman, AL + 33 other US sites
- Eligibility basics
- Ages 18–60
- RecruitingPhase 2/Phase 3
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
Alkermes, Inc.
- Location
- Cullman, AL + 32 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
AstraZeneca
- Location
- Cullman, AL + 53 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Eli Lilly and Company
- Location
- Cullman, AL + 59 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Eli Lilly and Company
- Location
- Cullman, AL + 22 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
Alkermes, Inc.
- Location
- Cullman, AL + 21 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
Alkermes, Inc.
- Location
- Cullman, AL + 21 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
AstraZeneca
- Location
- Cullman, AL + 120 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 3
Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)
Axsome Therapeutics, Inc.
- Location
- Cullman, AL + 37 other US sites
- Eligibility basics
- Ages 18–65